

Remi Mahmoud

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4377223/publications.pdf>

Version: 2024-02-01

11
papers

152
citations

1684188

5
h-index

1474206

9
g-index

11
all docs

11
docs citations

11
times ranked

233
citing authors

#	ARTICLE	IF	CITATIONS
1	No Association Between Pseudopolyps and Colorectal Neoplasia in Patients With Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2019, 156, 1333-1344.e3.	1.3	58
2	Association Between Indefinite Dysplasia and Advanced Neoplasia in Patients With Inflammatory Bowel Diseases Undergoing Surveillance. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1518-1527.e3.	4.4	26
3	Loss of response to anti-TNF \pm agents depends on treatment duration in patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1298-1308.	3.7	24
4	Immunomodulator Withdrawal From Anti-TNF Therapy Is Not Associated With Loss of Response in Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2577-2587.e6.	4.4	16
5	Surveillance and management of colorectal dysplasia and cancer in inflammatory bowel disease: Current practice and future perspectives. <i>European Journal of Internal Medicine</i> , 2021, 93, 35-41.	2.2	15
6	Continuation of Anti-TNF in Patients With Ulcerative Colitis in Remission Is Not Cost-effective Compared With Treatment Withdrawal: A Markov Model. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 709-718.	1.3	6
7	Editorial: missed opportunities to detect colorectal cancer in inflammatory bowel disease—getting to the root. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 335-336.	3.7	3
8	Reporting of patient characteristics and stratification factors in phase 3 trials investigating first-line systemic treatment of metastatic colorectal cancer: A systematic review. <i>European Journal of Cancer</i> , 2018, 96, 115-124.	2.8	2
9	Letter: loss of response to anti-TNF \pm agents depends on treatment duration in patients with inflammatory bowel disease—authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 499-500.	3.7	2
10	Editorial: risk of loss of response to anti TNF \pm in patients with inflammatory bowel diseases—“the longer the less? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 246-246.	3.7	0
11	Immunomodulator Withdrawal From Anti-TNF Therapy Needs A Careful Patient Selection—Authors' reply. <i>Clinical Gastroenterology and Hepatology</i> , 2022, , .	4.4	0